Previous 10 | Next 10 |
BeiGene signs deal with Singlomics for neutralizing COVID-19 antibodies BeiGene Ltd. ( BGNE ) announced that it has inked a new deal with Singlomics Biopharmaceuticals Co. for developing, manufacturing and commercializing various anti-COVID-19 antibodies, including DXP-593 and DXP-604. U...
UroGen (NASDAQ: URGN ) -3.8% in premarket, says Phase 2 trial of RTGel hydrogel formulation in combination with Botox did not meet the primary endpoint of improvement of overactive bladder (OAB) symptoms, as measured by the reduction in urinary incontinence episodes per day....
Trial Did Not Meet Primary Endpoint Believed to be the Result of BOTOX Not Effectively Permeating the Urothelium RTGel Delivered Treatment to the Bladder as Expected with Dwell Time of Up to 10 Hours UroGen and AbbVie will Continue to Explore Use of the RTGel Hydrogel Formulat...
Our analysis concludes the share prices of oncology-related companies are down, on average, 25% from peaking the third week of June 2020. With the exception of Agenus Inc. ( AGEN ), that appears to be trading higher on anticipation its vaccine adjuvant will be used in 2 or more of the eventual...
Image source: The Motley Fool. UroGen Pharma Ltd. (NASDAQ: URGN) Q2 2020 Earnings Call Aug 10, 2020 , 8:30 a.m. ET Operator Continue reading
UroGen Pharma Ltd. (URGN) Q2 2020 Earnings Conference Call Aug 10, 2020, 08:30 AM ET Company Participants Kate Bechtold - Senior Director, IR Liz Barrett - President & CEO Mark Schoenberg - Chief Medical Officer Jeff Bova - SVP, Commercial Peter Pfreundschuh - CFO Conf...
UroGen Pharma (NASDAQ: URGN ) : Q2 GAAP EPS of -$1.44 beats by $0.14 . More news on: UroGen Pharma Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...
Received U.S. FDA Approval of Jelmyto ® , the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) Successfully Commenced Launch of Jelmyto on June 1 st as Planned; Initial Commercial Performance Demonstrates Strong Executi...
Conference Call and Webcast Scheduled for Monday, August 10, 2020 at 8:30 AM ET UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases, today announced that it will report second quarter 202...
The following slide deck was published by UroGen Pharma Ltd. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 04:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...